Literature DB >> 21847048

Overview.

Frank C Detterbeck1, James Huang.   

Abstract

Mesh：

Year:  2011        PMID： 21847048     DOI： 10.1097/JTO.0b013e31821e7afe

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  5 in total

1.  Treatment updates in advanced thymoma and thymic carcinoma.

Authors:  Matthew A Gubens
Journal:  Curr Treat Options Oncol       Date:  2012-12

2.  Gemcitabine in patients previously treated with platinum-containing chemotherapy for refractory thymic carcinoma: radiographic assessment using the RECIST criteria and the ITMIG recommendations.

Authors:  Yusuke Okuma; Yukio Hosomi; Kageaki Watanabe; Satoshi Takahashi; Tatsuru Okamura; Tsunekazu Hishima
Journal:  Int J Clin Oncol       Date:  2015-12-08       Impact factor: 3.402

3.  Correlation between S-1 treatment outcome and expression of biomarkers for refractory thymic carcinoma.

Authors:  Yusuke Okuma; Yukio Hosomi; Shingo Miyamoto; Masahiko Shibuya; Tatsuru Okamura; Tsunekazu Hishima
Journal:  BMC Cancer       Date:  2016-02-25       Impact factor: 4.430

4.  Induction Therapy Followed by Surgery for Unresectable Thymic Epithelial Tumours.

Authors:  Shuai Wang; Jiahao Jiang; Jian Gao; Gang Chen; Yue Fan; Bei Xu; Jihong Dong; Shisuo Du; Junzhen Liu; Jianyong Ding
Journal:  Front Oncol       Date:  2022-01-05       Impact factor: 6.244

5.  Chemoradiotherapy for unresectable cases of thymic epithelial tumors: a retrospective study.

Authors:  Jumpei Kashima; Yusuke Okuma; Hiroto Murata; Kageaki Watanabe; Yukio Hosomi; Tsunekazu Hishima
Journal:  J Thorac Dis       Date:  2017-10       Impact factor: 2.895
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.